Study: Many approved cancer drugs lack proof of added benefit
Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedit...
Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedit...
Read More
Other Stories in General
- EU ‘far off the pace’ on chips targets, auditors find
- Tax incentives dominate company R&D support in OECD countries
- This week’s round up of quantum and AI calls
- Watch Hozier surprise Lucy Dacus in New York to perform ‘Bullseye’
- Report: Warriors' Jimmy Butler has deep glute contusion, status for Game 3 in jeopardy
- FIDE Social Chess Storytelling Challenge 2025: Every Move Counts
- NHL Game 2 Highlights: Maple Leafs 3, Senators 2 (OT)
- NHL Game 2 Highlights: Maple Leafs 3, Senators 2 (OT)
- 'A Lot of People Say They Can Play Megadeth's Music, and They Can't': What Dave Mustaine Looks for in a Guitar Player
